REC2 kinase
US6174694A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Sep 21, 1998 |
| Grant date | Jan 16, 2001 |
| Priority date | — |
| Expiry date | Sep 21, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/48
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.